Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: opioid  overdoses  drugs  aac  help  awareness  addiction  recovery  multivu  8130951  health  medicine  pharmaceuticals  gw  manufacturing  drugs  epileptic  treatment  pills  multivu  8109951  allergy  education  healthcare  safety  retail  xyzal  relief  medical  drugs  multivu  8029451  addiction  drugs  psa  help  support  family  ad  council  teens  school  multivu  8029751  livanova  medical  technology  therapy  health  treatment  drug  vns  epilepsy  multivu  7966451  health  medicine  company  chemicals  drugs  cancer  diabetes  disease  treatment  multivu  7809951  psa  hospice  support  fund  people  hospital  health  medical  treatments  multivu  7785451  zambia  light  school  education  children  third  world  natural  velux  little  sun  multivu  7769151  addiction  fighting  happiness  drugs  alcohol  funny  self  help  jerome  jay  isip  book  trailer  kids  drug  free  psa  maris  jones  hill  holliday  teen  underage  drinking  drugs  multivu  7103751  phrma  blood  cancer  rare  diseases  research  medicine  treatment  therapy  health  innovation  multivu  7350554  mark  wahlberg  millennium  health  prescription  drugs  medicine  medication  misuse  abuse  teens  kids  multivu  7071752 
Search // drugs
Results 1-12 of 68 for ' drugs ' (1 seconds)
Each day in the U.S. 91 people die from an opioid-related overdose, and the numbers are increasing. In observance of International Overdose Awareness Day on August 31, American Addiction Centers (AAC) and Recovery Brands are launching a nationwide awareness campaign on how to prevent deaths from opioid overdoses. The campaign features shareable online resources, including an animation video about how an overdose impacts a body, an infographic about how to administer overdose medication, and powerful videos of survivors sharing the life-saving lessons they learned during their darkest hours. “This is a meaningful endeavor as we partner with our parent company, AAC, in order to present several life-saving resources for people impacted by addiction,” said Ruchi Dhami, director of market insights and development at Recovery Brands, a provider of digital addiction treatment resources. “Since such a large amount of individuals look for information online about addiction and treatment, we wanted to ensure comprehensive education surrounding opioid overdoses existed and is easily accessible for individuals and families impacted by addiction.” To view the multimedia release go to: https://www.multivu.com/players/English/8130951-american-addiction-centers-opioid-overdose/
Categories // Miscellaneous 
Added: 36 days ago by MultiVuVideos
Runtime: 2m32s | Views: 7 | Comments: 0
Not yet rated
 

 

 

GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience. To view the multimedia release go to: https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
Categories // Miscellaneous 
Added: 118 days ago by MultiVuVideos
Runtime: 3m35s | Views: 2 | Comments: 0
Not yet rated
 

 

 

Sanofi Consumer Healthcare – the makers of new Xyzal® Allergy 24HR, which is now available on retail shelves nationwide – revealed today the results of a social experiment in which 160 participants (80 allergy sufferers and 80 non-sufferers) wore a wearable device for 30 days to track their sleep and activity. The first-of-its-kind experiment found allergy symptoms can impact various elements of sufferers’ lives, including both the quality of their sleep and their daytime activities. Xyzal is partnering with renowned allergist Dr. Neeta Ogden to encourage allergy sufferers to Wise Up about the importance of managing their allergies this spring, so they can have a better night’s sleep and Rise Up in the morning to take on the day. To view the multimedia release go to: https://www.multivu.com/players/English/8029451-sanofi-xyzal-allergy-social-experiment-wise-up-rise-up/
Categories // Miscellaneous 
Added: 184 days ago by MultiVuVideos
Runtime: 1m4s | Views: 6 | Comments: 0
Not yet rated
 

 

 

The Ad Council, the largest producer of public service campaigns in the U.S., in partnership with Viacom, home to premier global brands in media and entertainment, and non-profit leader Facing Addiction today launched the PSA campaign “LISTEN” to ignite a national conversation about drug and alcohol addiction as a public health epidemic, and empower those impacted by substance use disorders. While past PSA campaigns have traditionally focused on the perspective of those at risk, urging them to eliminate all substance use, “LISTEN” addresses the support system of people who are also affected by this crisis. Using powerful stories that portray the modern faces of addiction and recovery, the campaign looks to remove the stigma attached to substance misuse through the act of informed, compassionate listening. The campaign’s website, heretolisten.com, and Facing Addiction's Resource Hub provides important tools and information to help people start a productive conversation with their friends and loved ones and to support the more than 45 million Americans directly impacted by addiction. To view the multimedia release go to: http://www.multivu.com/players/English/8029751-ad-council-listen-psa-addiction-drug-alcohol-substance-abuse/
Categories // Miscellaneous 
Added: 232 days ago by MultiVuVideos
Runtime: 1m0s | Views: 8 | Comments: 0
Not yet rated
 

 

 

LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world. One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom. “Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.” To view the multimedia release go to: http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
Categories // Miscellaneous 
Added: 315 days ago by MultiVuVideos
Runtime: 5m11s | Views: 57 | Comments: 0
Not yet rated
 

 

 

Eli Lilly and Company (NYSE: LLY) will commemorate its 140th anniversary today with activities at Lilly locations worldwide, including a ceremony to unveil a statue dedicated to founder Colonel Eli Lilly at global headquarters in Indianapolis. Over 14 decades, the organization has contributed more than 100 medicines and significant medical advances, such as the first commercially available insulin, manufacturing and global distribution of the Salk polio vaccine and mental health breakthroughs such as anti-depressant Prozac® (fluoxetine). Today Lilly continues to progress its most robust pipeline in history with dozens of potential new medicines in mid- to late-stage development for cancer, diabetes, autoimmune disease, pain and Alzheimer’s disease. “As Lilly celebrates 140 years, we’re keeping the vision of our founder alive – from our dedication in the lab to our impact in the community,” said John C. Lechleiter, Ph.D., Lilly chairman, president and chief executive officer, who began his career at Lilly as a chemist in 1979. “Colonel Eli Lilly started this company to put science to work fighting disease and encouraged his successors to ‘take what you find here and make it better and better.’ That vision pushes us daily to honor Colonel Lilly’s legacy and continue in our quest to discover new medicines to help make life better.” To view the multimedia release go to: http://www.multivu.com/players/English/7809951-eli-lilly-and-company-140th-anniversary/
Categories // Miscellaneous 
Added: 499 days ago by MultiVuVideos
Runtime: 2m30s | Views: 136 | Comments: 0
Not yet rated
 

 

 

Over 80% of Americans want to spend their last days at home, with friends and family. Yet, despite these desires, 75% of Americans will spend their last days in a hospital room. Many people will spend hours each day getting painful and often useless treatments and tests, and be asked to take dozens of debilitating drugs. For many, the cure is worse than the disease. This often has negative and lasting effects on family and friends who are often left with feelings of guilt and regret for years to come. Hospice Support Fund is a 501(c)(3) non-profit organization dedicated to promoting end of life care at home rather than in a hospital so patients can spend their last days in dignity and peace, pain-free in familiar, comfortable surroundings with friends and family. To view the multimedia release go to: http://www.multivu.com/players/English/7785451-hospice-support-fund-end-of-life-care-psa/
Categories // Miscellaneous 
Added: 531 days ago by MultiVuVideos
Runtime: 1m7s | Views: 154 | Comments: 0
Not yet rated
 

 

 

Globally, 1.2 billion people have no access to electricity. On the occasion of VELUX 75th anniversary the company decided to address this issue. Together with the social business Little Sun and the NGO Plan International they are collaborating to bring clean, reliable and affordable light to off-grid regions in Zambia, Sierra Leone and Zimbabwe. 14,500 Natural Light lamps from the VELUX Group have now arrived in Africa and the first recipients can already look forward to a better quality of life. Among them are young girls between 10 and 18 years of age who live in a safe house in the slum area Mntendere in the Zambian capital Lusaka. "The lamps mean the girls can do their homework when they get back from school and can feel safer at night, instead of huddling together in the dark after sunset. And it’s particularly important for our children that they feel safe – many are carrying the mental baggage such as the trauma of violence, rape or drugs," says safe house manager Verann Delarey. To view the multimedia release go to: http://www.multivu.com/players/uk/7769151-velux-natural-light-and-life-zambia/
Categories // Miscellaneous 
Added: 573 days ago by MultiVuVideos
Runtime: 0m48s | Views: 231 | Comments: 0
Not yet rated
 

 

 

This candid, autobiographical book tells of Jay’s journey to find his identity and his own version of “happy” in early adulthood through self-destructive means like alcohol, a myriad of drugs, and other risky behavior, and how he pulled himself back from the edge of the abyss, finding the courage to live a life of clarity and purpose after discovering what true, lasting happiness in life is all about. Find out more at -http://www.amazon.com/Jerome-Jay-Isip/e/B00PB2P6SS/ref=ntt_dp_epwbk_1 Biography, Memoir, Self-Help
Categories // Miscellaneous 
Added: 601 days ago by cosproductions
Runtime: 1m23s | Views: 150 | Comments: 0
Not yet rated
 

 

 

The Partnership for Drug-Free Kids, a national nonprofit dedicated to reducing substance abuse among adolescents, today launched a new multimedia campaign for teens that illustrates some of the pressures they face, including peer pressure to drink and use drugs, issues with body image and bullying, among others. The “Who Controls You” campaign breaks this month and was created pro-bono by advertising agency, Hill Holliday and award-winning, social media influencer, Maris Jones, as part of the Partnership’s Above the Influence (ATI) teen program. “We are incredibly proud of this work. We struck gold when Hill Holliday collaborated with Adolescent Media and Maris Jones to bring this campaign to life,” said Chief Marketing Officer for the Partnership for Drug-Free Kids, Kristi Rowe. “Partnering with a young, talented social media influencer like Maris lent such a unique and authentic voice to this effort. Combining the extraordinary insight and passion of the Hill Holliday team with Maris’ distinct artistry brought an unexpected style to the campaign that makes this creative truly break through.” To view the multimedia release go to: http://www.multivu.com/players/English/7103751-drug-free-partnership-who-controls-you/
Categories // Miscellaneous 
Added: 679 days ago by MultiVuVideos
Runtime: 0m30s | Views: 190 | Comments: 0
Not yet rated
 

 

 

Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations. The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350554-phrma-report-innovation-rare-diseases/
Categories // People and Blog 
Added: 938 days ago by MultiVuVideos
Runtime: 2m6s | Views: 303 | Comments: 0
Not yet rated
 

 

 

Millennium Health, a leading health solutions company, today announced the launch of the Drop Them Off campaign, in partnership with the Mark Wahlberg Youth Foundation and the Partnership for Drug-Free Kids’ Medicine Abuse Project. Designed to increase awareness of the problem of youth misuse and abuse of prescription medicine, the campaign intends to educate parents and youth on how to properly use, store, and dispose of prescription medications by dropping them off at appropriate collection sites among other methods, to reduce access and opportunity for misuse or abuse. Educational content will be available online (www.DropThemOff.com) and through curriculum delivered through the Mark Wahlberg Youth Foundation’s community-based partners. Millennium Health is a Silver Sponsor of the Medicine Abuse Project, a campaign that aims to prevent half a million teens from abusing medicine by 2017. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7071752-millennium-health-drop-them-off/
Categories // People and Blog 
Added: 961 days ago by MultiVuVideos
Runtime: 0m20s | Views: 292 | Comments: 0
Not yet rated
 

 

 

Page 1 of 6  |  Go to page    Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2017 ClipMoon.com. All rights reserved.